Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Illerhaus

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Hematological Oncology|June 11, 2015
III. Current concepts in primary central nervous lymphomaGerald Illerhaus
Blood|February 25, 2021
CNS relapse in DLBCL: a calculable risk?Gerald Illerhaus
The Lancet. Oncology|January 12, 2019
CNS border posts against rituximab?Benjamin Kasenda, Gerald Illerhaus
Blood|March 19, 2011
PCNSL: biomarker better than biopsy?Gerald Illerhaus, Tracy Batchelor
Blood|July 11, 2018
Novel agents for primary central nervous system lymphoma: evidence and perspectivesGerald Illerhaus, Elisabeth Schorb, Benjamin Kasenda
Blood|February 3, 2016
The role of autologous stem cell transplantation in primary central nervous system lymphomaAndrés J M Ferreri, Gerald Illerhaus
Deutsche Medizinische Wochenschrift (1946)|February 1, 2019
[Current Treatment Standards in PCNSL]Elisabeth Schorb, Gerald Illerhaus, Jürgen Finke
Oncology Research and Treatment|April 29, 2025
Highlights from ESMO 2024 as a Young Head and Neck OncologistMahdi Yassine, Gerald Illerhaus, Dennis Hahn
The Cochrane Database of Systematic Reviews|November 16, 2012
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)Nicole Bergner, Ina Monsef, Gerald Illerhaus, et al.
Nature Reviews. Clinical Oncology|August 12, 2010
Flows and flaws in primary central nervous system lymphomaAndrés J M Ferreri, Gerald Illerhaus, Emanuele Zucca, et al.
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Hematological Oncology|June 11, 2015
III. Current concepts in primary central nervous lymphomaGerald Illerhaus
Blood|February 25, 2021
CNS relapse in DLBCL: a calculable risk?Gerald Illerhaus
The Lancet. Oncology|January 12, 2019
CNS border posts against rituximab?Benjamin Kasenda, Gerald Illerhaus
Blood|March 19, 2011
PCNSL: biomarker better than biopsy?Gerald Illerhaus, Tracy Batchelor
Blood|July 11, 2018
Novel agents for primary central nervous system lymphoma: evidence and perspectivesGerald Illerhaus, Elisabeth Schorb, Benjamin Kasenda
Blood|February 3, 2016
The role of autologous stem cell transplantation in primary central nervous system lymphomaAndrés J M Ferreri, Gerald Illerhaus
Deutsche Medizinische Wochenschrift (1946)|February 1, 2019
[Current Treatment Standards in PCNSL]Elisabeth Schorb, Gerald Illerhaus, Jürgen Finke
Oncology Research and Treatment|April 29, 2025
Highlights from ESMO 2024 as a Young Head and Neck OncologistMahdi Yassine, Gerald Illerhaus, Dennis Hahn
The Cochrane Database of Systematic Reviews|November 16, 2012
Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL)Nicole Bergner, Ina Monsef, Gerald Illerhaus, et al.
Nature Reviews. Clinical Oncology|August 12, 2010
Flows and flaws in primary central nervous system lymphomaAndrés J M Ferreri, Gerald Illerhaus, Emanuele Zucca, et al.
Pageof 8